Should I Buy BDX? BDX 2026 Analysis

Should You Buy Becton Dickinson and Co (BDX) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

210.020

1 Day change

1.70%

52 Week Range

235.340

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now at ~208.5 pre-market: price is pressing into nearby resistance (next key level ~210.65) while momentum is not cleanly bullish (MACD still negative).
Options positioning is constructive (call-leaning put/call ratios), but not strong enough to override the technical setup and heavy insider selling trend.
Near-term catalyst risk/reward is dominated by the upcoming earnings (2026-02-11 pre-market) and the LifeSciences Bioprocessing sale/spin-related repositioning; with an impatient profile, this is not an ideal “buy-now” setup.
Intellectia Proprietary Trading Signals
- AI Stock Picker: no signal on given stock today.
- SwingMax: No signal on given stock recently.

Technical Analysis

Current price (pre-market): ~208.5, above Pivot 202.613 and above R1 207.581; next resistance is R2 210.65 (near-term upside may be capped until a clean breakout).
MACD histogram: -0.4 (below 0) but negatively contracting → downside momentum is fading, but trend has not flipped bullish yet.
RSI(6): 63.36 (neutral-to-bullish) → supports mild upside bias, but not an “oversold bounce” setup.
Moving averages: converging → consolidation/indecision; typically needs a breakout confirmation.
Key levels to watch: Support S1 ~197.645; Pivot ~202.613; Resistance ~210.65.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Sentiment tilt: Put/Call ratios (OI 0.69; Volume 0.47) imply more call interest/flow than puts (bullish lean).
Volatility: IV30 ~25.51 vs HV ~21.62 → options pricing implies moderately higher forward volatility.
Activity: today’s volume (324) is below recent averages (5d avg ~725.8; 10d avg ~618.4) → sentiment signal is positive, but not backed by unusually heavy volume.
IV percentile ~60.8 (mid-high) → options are not “cheap,” but also not extreme.

Technical Summary

Sell

Buy

Positive Catalysts

supports a “simplification/focus” narrative.
showed strong growth: revenue +8.35% YoY; net income +23.25% YoY; EPS +24.82% YoY; gross margin improved.

Neutral/Negative Catalysts

without a confirmed bullish MACD crossover.

Financial Performance

Latest quarter: 2025/Q4
Revenue: $5.891B, +8.35% YoY (solid top-line growth).
Net income: $493M, +23.25% YoY (profit growth outpacing revenue).
EPS: $1.71, +24.82% YoY (strong earnings leverage).
Gross margin: 47.51%, +2.30% YoY (improving profitability trend).

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent trend: price targets have generally moved up into early 2026, with a notable new/resumed bullish call from Citi.
Bullish/pro view: Citi Buy $233; Stifel Buy $215; Morgan Stanley Overweight $210 → thesis centers on improved MedTech setup and a more focused company post-transaction.
Neutral/mixed view: Piper Neutral $205; BofA Neutral $207; RBC Sector Perform $210 → acknowledges durable core and mid-single-digit growth, but reflects ongoing headwinds and execution/guidance sensitivity.
Bottom line from Wall Street: pros like the focus/catalyst and steady MedTech demand; cons focus on lingering headwinds and the need to see post-change execution deliver consistent growth.

8 Analyst Rating

Wall Street analysts forecast BDX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for BDX is 202.38 USD with a low forecast of 183 USD and a high forecast of 220 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

5 Hold

0 Sell

Moderate Buy

Current: 206.510

Low

183

Averages

202.38

High

220

Current: 206.510

Low

183

Averages

202.38

High

220

Citi

NULL

Buy

initiated

$233

AI Analysis

2026-02-02

Reason

Citi

Price Target

$233

AI Analysis

2026-02-02

initiated

NULL

Buy

Reason

Citi resumed coverage of Becton Dickinson (BDX) with a Buy rating and $233 price target. Becton Dickinson's sale of its LifeSciences Bioprocessing segment to Waters Corp (WAT), closing February 9, 2026, creates a pure-play MedTech company that still participates in Medical Essential, Connected Care, Biopharma Systems, and Interventional, the analyst tells investors in a research note. Spin-outs generally create a more focused company, freeing the parent to deliver faster, more consistent growth, and this should be true for Becton Dickinson, the firm added.

Piper Sandler

Jason Bednar

Neutral

maintain

$190 -> $205

2026-01-28

Reason

Piper Sandler

Jason Bednar

Price Target

$190 -> $205

2026-01-28

maintain

Neutral

Reason

Piper Sandler analyst Jason Bednar raised the firm's price target on Becton Dickinson (BDX) to $205 from $190 and keeps a Neutral rating on the shares. The firm notes the company changed its business unit reporting methodology beginning Q1-26, and Piper is updating its model to reflect that new approach. Note that the firm's estimates continue to include the Life Sciences unit, which is finding a new home with Waters (WAT) in a couple weeks.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for BDX

Unlock Now

BDX Should I Buy

BDX Should I Buy

Should You Buy Becton Dickinson and Co (BDX) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch